公司持股 5%以上股东陈浩华保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 证券代码：002950 证券简称：奥美医疗 公告编号：2025-040 奥美医疗用品股份有限公司 关于持股 5%以上股东权益变动暨 披露简式权益变动报告书的提示性公告 1.本次权益变动属于公司持股 5%以上股东陈浩华先生将其持有的公司股份 通过大宗交易形式减持导致其持有公司股份数量和比例减少。 2.本次权益变动不涉及控股股东及一致行动人增持或减持，不触及要约收 购，不会导致公司控股股东及实际控制人发生变化，不会影响公司的治理结构 和持续经营。 3.关于本次权益变动的具体内容详见公司同日在巨潮资讯网披露的《简式 权益变动报告书》。 1.陈浩华先生本次权益变动遵循减持计划公告，与此前披露的减持计划一 致，符合《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动 报告书（2025 年修订）》等有关规定的情形。 2.本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发 生变化，不会影响公司的治理结构和持 ...

8月1日，奥美医疗今日收盘9.36元，上涨1.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.41倍，创95天以来新低，总市值59.27亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，奥美医疗排 名第37位。 股东方面，截至2025年3月31日，奥美医疗股东户数39155户，较上次减少2201户，户均持股市值35.28 万元，户均持股数量2.76万股。 奥美医疗用品股份有限公司的主营业务是医用耗材及一次性医疗器械、感染防护用品、家庭护理产品的 研发、生产和销售。公司的主要产品是外科与伤口护理、感染防护、高级敷料、卫生护理。2020年11 月，公司"医用敷料智能工厂"项目入选2020年湖北省人工智能十大优秀应用案例（颁发单位：湖北省经 济和信息化厅）；2021年2月，公司获评"湖北省支柱产业细分领域隐形冠军科技小巨人（2020- 2022）"；2022年11月，奥美医疗名列"2022湖北民营企业制造业100强榜单"；2023年2月奥美医疗获 得"2022年度中国产学研合作创新成果优秀奖"；2023年11月，奥美医疗再度荣列工信部2022 ...

Core Viewpoint - Aomei Medical's stock price closed at 9.26 yuan on July 31, 2025, reflecting a decrease of 0.54% from the previous trading day, with a trading volume of 54,716 lots and a transaction amount of 0.51 billion yuan [1] Company Overview - Aomei Medical specializes in the research, production, and sales of disposable medical consumables, including wound care, surgical infection control, and infection prevention products, with a global market presence [1] - The company has maintained its leading position in China's medical dressing export industry for 17 consecutive years [1] Recent Developments - Aomei Medical has signed a strategic cooperation agreement with the German Lohmann & Rauscher Group to acquire 100% equity of its wholly-owned subsidiary in China, gaining exclusive agency rights for related products in the Chinese market [1] - This collaboration will enhance Aomei Medical's product line in China, particularly in the fields of wound management, pressure treatment, and external fixation [1] - The partnership builds on a commercial cooperation foundation established since 2006, indicating a deepening of the relationship between the two companies [1]

Core Viewpoint - Aomei Medical has signed a comprehensive cooperation agreement with Lohmann & Rauscher Group, marking a significant strategic partnership that includes the acquisition of Lohmann & Rauscher's wholly-owned subsidiary in China and exclusive agency rights for various medical products in the region [1][2]. Group 1: Strategic Partnership - The partnership involves Aomei Medical acquiring 100% of Lohmann & Rauscher (China) Medical Supplies Co., Ltd. and gaining exclusive agency rights for wound management, pressure treatment, and external fixation products in China [1]. - This collaboration is a continuation of their strategic cooperation that began with a functional dressing business partnership in November 2024, further solidifying their multi-layered strategic alliance [1][2]. Group 2: Market Position and Product Development - Aomei Medical has been focusing on the research and manufacturing of functional dressings, launching innovative products such as soft silicone foam dressings and hydrocolloid dressings, which cater to various wound care scenarios [2]. - The partnership enhances Aomei Medical's product pipeline in the wound management sector and allows entry into new fields like pressure treatment and external fixation, significantly boosting its competitive edge in the Chinese market [2]. Group 3: Leadership Perspectives - The CEO of Lohmann & Rauscher Group expressed confidence that the partnership will lead to higher quality and more sustainable product development, highlighting Aomei Medical's production capabilities [2]. - Aomei Medical's chairman emphasized that this collaboration marks a new beginning in the healthcare sector, aiming for significant achievements in expanding their market presence in China [3].

Core Viewpoint - The recent large block trades in Aomei Medical (002950) indicate significant institutional buying activity, suggesting potential long-term investment interest despite the stock's price discount compared to market value [1][2]. Group 1: Trading Activity - On July 30, Aomei Medical experienced 7 large block trades totaling 5.04 million shares, with a transaction value of 42.99 million yuan, at an average price of 8.53 yuan per share, representing an 8.38% discount to the closing price of 9.31 yuan [1]. - Institutional investors accounted for 6 of the trades, purchasing 4.64 million shares worth 39.58 million yuan, which is 92% of the total transaction value [1]. - The stock's trading volume on the same day was 55.66 million yuan, with large block trades making up 77.24% of this volume [1]. Group 2: Shareholder Activity - On July 21, shareholder Chen Haohua reduced his stake by 4.21 million shares, representing 0.67% of the total share capital, bringing his holding to 10.87% [2]. - The subsequent three days of large block trades were linked to the same brokerage firm involved in Chen's share reduction, indicating that institutions may have been the primary buyers of the sold shares [2]. Group 3: Market Context and Financial Performance - The overall market saw high activity in large block trades, with companies like China Merchants Bank and Hengli Petrochemical also reporting significant transactions [2]. - As of July 30, Aomei Medical's stock price slightly increased by 0.11% to 9.31 yuan, with a total market capitalization of 5.896 billion yuan and a price-to-earnings ratio of 17.04 [2]. - For the first quarter of 2025, Aomei Medical reported revenues of 759 million yuan and a net profit of 86.5 million yuan [2].

来源:金融界 7月29日，奥美医疗发生一笔大宗交易，成交46.9万股，成交金额400.06万元，成交价8.53元，较当日收 盘价折价8.28%，买方为机构专用账户。当日主力资金净流出186.21万元。 风险提示：股市有风险，投资需谨慎。 截至2025年7月29日收盘，奥美医疗股价报9.30元，较前一交易日上涨0.43%。当日成交量为46085手， 成交金额4262.76万元，振幅1.62%。 奥美医疗主要从事医用敷料等一次性医用耗材的研发、生产和销售，产品涵盖伤口护理、手术感控等领 域。公司产品远销多个国家和地区。 ...

7月29日，奥美医疗大宗交易成交46.9万股，成交额400.06万元，占当日总成交额的8.58%，成交价8.53元，较市场收盘价9.3 元折价8.28%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-07-29 | 002950 | 奥美医疗 | 8.53 | 46.90 | 400.06 | 机构专用 | 东方证券股份有限 | | | | | | | | | 公司深圳深南大道 | | | | | | | | | 证券营业部 | ...

Group 1 - The core viewpoint of the news highlights the current financial performance and market position of Aomei Medical, indicating a low PE ratio compared to the industry average [1][3] - As of July 24, Aomei Medical's stock closed at 9.2 yuan, with a PE ratio of 16.13, marking a 76-day low, and a total market capitalization of 5.826 billion yuan [1] - The medical device industry has an average PE ratio of 54.55, with Aomei Medical ranking 34th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan [3]

5. 超捷股份(301005.SZ)：股东泰州誉威、泰州文超及宋毅博减持计划已实施完毕，累计减持320.17万 股，占总股本的2.38%。 6. 广联达(002410.SZ)：控股股东刁志中及董事刘谦、云浪生、王爱华计划15个交易日后3个月内，以集 中竞价或大宗交易方式分别减持不超过3280万股、60万股、15万股和50万股。 7. 贵州燃气(600903.SH)：股东北京东嘉及贵阳工投计划15个交易日后3个月内，以集中竞价及大宗交易 方式减持股份不超过3450万股，占公司总股本的3%。 1. 奥美医疗(002950.SZ)：股东陈浩华于7月21日通过大宗交易减持421.40万股，占总股本的0.67%，减持 后持股比例降至10.87%。 2. 贝仕达克(300822.SZ)：股东创新一号及创新二号计划15个交易日后3个月内，以集中竞价及大宗交易 方式减持股份不超过929.8731万股，占公司总股本的3%。 3. 博盈特焊(301468.SZ)：股东深圳战兴基金自2025年4月25日披露减持计划以来，已累计减持261.60万 股，占总股本的1.98%，减持计划时间届满。 4. 常山北明(000158.SZ)：副 ...

Group 1 - The core point of the announcement is that Chen Haohua, a shareholder holding more than 5% of the shares, has reduced his stake in Aomei Medical by 4.214 million shares, bringing his total holdings to 68,836,321 shares, which is 10.87% of the total share capital [1][2][3] - The reduction occurred on July 21, 2025, through a block trade, and is in compliance with relevant laws and regulations [1][4] - This reduction will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [2][5] Group 2 - Prior to this reduction, Chen Haohua held 73,050,300 shares, representing 11.54% of the total share capital [3][5] - The total planned reduction includes up to 18,562,734 shares, with this transaction being part of a previously disclosed plan [4][5] - The announcement confirms that the current reduction aligns with previously disclosed intentions and commitments [5]